Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Apalutamide was associated with an improved 24-month overall survival rate vs enzalutamide in metastatic castration-sensitive prostate cancer.

Apalutamide Demonstrates Real-World OS Benefit vs Enzalutamide in mCSPC

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

A phase 2 study of intermittent ibrutinib dosing shows reducing cardiovascular toxicity while maintaining efficacy in CLL.

Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Idoroenyi Amanam, MD, discusses characteristics that make patients with myelofibrosis most likely to derive benefit from certain JAK inhibitors.

JAK Inhibitors Diversify the Field of Myelofibrosis Symptom and Spleen Management

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Evolving Treatment Strategies in High-Risk Neuroblastoma

Videos

Giselle Sholler, MD, and Anurag Agrawal, MD, discuss the changing landscape of treatment strategies for patients with high-risk neuroblastoma and review key clinical trial data presented at the ASCO 2023 Annual Meeting.

Giselle Sholler, MD, provides an overview of neuroblastoma, highlighting that 50% of all diagnosed cases in the US are considered high-risk, with a relapse rate of over 40%.

An Overview of Neuroblastoma

Anurag Agrawal, MD, explains his approaches to diagnosing neuroblastoma, including urine markers, imaging, and bone marrow sampling, and emphasizes age and disease dissemination as major prognostic indicators alongside genetic predisposition and treatment response.

Approaches to Diagnosing Neuroblastoma

Dr Giselle Sholler details the role of CURIE scores in measuring bone disease and metastatic spread in neuroblastoma, with a score greater than 12 indicating a worse prognosis.

Role of CURIE Scores in the Treatment and Management of Neuroblastoma

Giselle Sholler, MD, outlines the currently available treatment options for neuroblastoma based on a patient’s risk status.

Current Treatment Paradigm for Newly Diagnosed Neuroblastoma

Anurag Agrawal, MD, discusses how refractory and relapsed neuroblastoma is differentiated, and the typical treatment approaches for both.

Differentiating Refractory and Relapsed Neuroblastoma

Experts review updated data from the LEAHRN study presented at the ASCO 2023 Annual Meeting highlighting the long-term toxicities experienced by high-risk neuroblastoma patients, particularly hearing loss, and the potential to modify treatments to reduce these effects.

Updated Data From the LEAHRN Study in High-Risk Neuroblastoma

Key opinion leaders address the treatment of recurrent or relapsed high-risk neuroblastoma, emphasizing the efficacy of antibody therapies naxitamab and dinutuximab, which target neuroblastoma cells, and the significance of post-induction therapy to enhance patient outcomes before transplantation.

Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

Drs Sholler and Agrawal detail recent studies on naxitamab and dinutuximab demonstrating effectiveness in treating recurrent or refractory neuroblastoma, leading to their FDA approvals, and significantly influencing treatment practices.

Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.

Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

Giselle Sholler, MD, and Anurag Agrawal, MD, close their discussion with a look at the future of neuroblastoma treatment, highlighting research being done in areas such as immunotherapies, CAR T-cell therapy, and genomics for more targeted approaches aiming to enhance patient outcomes.

Future Perspectives in the Treatment of Neuroblastoma

Current Treatment Paradigm for Newly Diagnosed Neuroblastoma

EP: 1.An Overview of Neuroblastoma

EP: 2.Approaches to Diagnosing Neuroblastoma

EP: 3.Role of CURIE Scores in the Treatment and Management of Neuroblastoma

EP: 4.Current Treatment Paradigm for Newly Diagnosed Neuroblastoma

EP: 5.Differentiating Refractory and Relapsed Neuroblastoma

EP: 6.Updated Data From the LEAHRN Study in High-Risk Neuroblastoma

EP: 7.Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

EP: 8.Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

EP: 9.Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

EP: 10.Future Perspectives in the Treatment of Neuroblastoma

Latest Conference Coverage